Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from HIMS

What's Going On With Shares Of Hims & Hers Health Thursday?

Shares of Hims Hers Health, Inc. (NASDAQ:HIMS) are trending Thursday morning. The San Francisco-based telehealth company announced an international expansion.

Benzinga

Hims, Block, and NRG Just Launched Huge Stock Buybacks

Buyback capacity just got a big-time boost at Hims, Block, and NRG Energy. The three firms authorized more than $8 billion in buybacks combined.

MarketBeat

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing

Hims Hers Health, Inc. (NYSE:HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.

Benzinga

Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants

One of the more popular ideas floating around on Wall Street, Hims Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong demand for weight-loss treatments. However, it's also a speculative investment, with the wellness platform facing a crowded digital health…

Benzinga

Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results

Hims & Hers Health delivered a mixed earnings report and announced a potential Wegovy partnership with Novo Nordisk; the downside risk to HIMS stock looks low.

MarketBeat

Stock Market Today: Dow Jones, Nasdaq Futures Rise After Stellar October Gains— Micron Technology, Palantir, Hims & Hers In Focus (UPDATED)

Editor’s Note: The future prices of benchmark tracking ETFs and the headline were updated in the story.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

United Airlines pilot accused of DUI sues airline for racial discrimination because they won’t let him fly

The former United pilot says the airline discriminated against him based on a perceived disability and his race

The Independent UK

Hims & Hers Short Interest Nears All-Time High, Buy The Dip?

Hims & Hers stock is falling well off its 52-week highs, as bears lean on the CEO's scheduled sale that just took place, though it might be a mistake.

MarketBeat

CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You?

Insider selling tests investor confidence as Hims & Hers faces valuation pressure and shifting GLP-1 momentum.

Barchart

Why Hims & Hers Health Shares Are Sliding Friday

Shares of Hims Hers Health Inc (NYSE:HIMS) are trading lower Friday morning after comments from President Donald Trump indicated that he expects the prices of popular weight-loss drugs to decrease. Here’s what investors need to know.

Benzinga

Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem

Hims Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this time is not another flashy partnership — it's a rally built from within.

Benzinga

How To Buy HIMS For A 24% Discount, Or Achieve an 82% Annual Return

Yesterday, with Hims & Hers Health (HIMS) trading at $62.76, the November 7 put option with a strike price of $50 was trading around $2.45. Traders selling this put would receive $245 in option premium.

Barchart

Investors Are Buying Hims & Hers Health Stock Following Wednesday's Platform Expansion Announcement

Hims Hers Health Inc (NYSE:HIMS) shares are trading higher Wednesday following the company’s launch of a new menopause and perimenopause care specialty on its Hers platform.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

3 Healthcare Stocks Using AI to Drive Growth

AI is reshaping healthcare by improving outcomes and easing burnout. See how three companies are leading this transformation

Benzinga

Hims & Hers Powers YieldMax's Latest Options-Based Income ETF

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).

Barchart

HIMS Stock Just Got Rocked (Again) By the FDA. This Analyst Still Thinks Hims & Hers Can Surge 50%.

Despite a sharp selloff after the latest FDA warning, Hims & Hers continues to post triple-digit annual gains and strong revenue growth, with at least one analyst projecting a 50% upside.

MarketBeat

3 Big Short Interest Names With Bullish Setups

HIMS, DLO, and TEM combine high short interest with bullish chart setups, creating strong breakout potential as market momentum stays hot.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy

Hims & Hers Health posted 73% revenue growth and 31% more subscribers in Q2. With analyst targets hitting $68, is now the time to buy HIMS?

Benzinga

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds

Oscar Health Inc (NYSE:OSCR) just became one of Wall Street's buzziest policy trades. With ACA (Affordable Care Act) subsidy chatter swirling ahead of a possible government shutdown, the tech-driven insurer is drawing Hims Hers Health Inc (NYSE:HIMS) style moonshot comparisons — and short sellers may be sitting on a powder…

Benzinga

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Benzinga

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum.

The Independent UK

FDA takes aim at Hims and other telehealth services in drug advertising blitz

The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy

Benzinga

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks

Food and Drug Administration Commissioner Martin Makary stated on Friday that Hims Hers Health Inc. (NYSE:HIMS) broke federal law with its Super Bowl commercial promoting weight-loss drugs.

Benzinga

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims Hers Health Inc. (NYSE:HIMS) launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.